SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives $10.00 Average Price Target from Analysts

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $10.00.

Several analysts have commented on the stock. Guggenheim started coverage on shares of SAB Biotherapeutics in a research report on Friday, December 19th. They set a “buy” rating and a $15.00 price target for the company. Wall Street Zen downgraded shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. HC Wainwright reduced their price objective on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, March 10th. Zacks Research cut shares of SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, March 12th. Finally, Chardan Capital raised their target price on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th.

Institutional Trading of SAB Biotherapeutics

Institutional investors have recently made changes to their positions in the business. State of Wyoming purchased a new position in SAB Biotherapeutics during the 4th quarter worth $34,000. ADAR1 Capital Management LLC raised its stake in SAB Biotherapeutics by 75.6% in the fourth quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after buying an additional 11,344 shares during the last quarter. State Street Corp acquired a new stake in SAB Biotherapeutics in the fourth quarter worth about $49,000. Fifth Lane Capital LP acquired a new stake in SAB Biotherapeutics in the fourth quarter worth about $56,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics during the third quarter worth about $32,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Down 9.1%

Shares of NASDAQ SABS opened at $3.70 on Friday. SAB Biotherapeutics has a 12-month low of $1.00 and a 12-month high of $6.60. The stock’s fifty day simple moving average is $4.03 and its two-hundred day simple moving average is $3.41. The stock has a market capitalization of $188.52 million, a PE ratio of -1.59 and a beta of 0.59. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 0.02.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.30). As a group, analysts expect that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.